1568P Clinical and laboratory outcomes of solid cancer patients reinfected with SARS-CoV-2

2021 
Background: COVID-19 reinfection has been increasingly reported. Immunocompromised patients may be more susceptible to COVID-19 reinfection due to impaired immune responses to the virus. The current study aimed to evaluate the clinical and laboratory outcomes of solid cancer patients who were reinfected with COVID-19. Methods: Patients with a diagnosis of solid cancer and COVID-19 PCR positive were screened. The patients enrolled whether patient has at least one negative COVID-19 PCR test and clinical improvement. In addition to that at least 28 days after the previous positive COVID-19 PCR result, the patient must have a confirmed COVID-19 PCR positive result again. Results: Total 1024 patients with COVID-19 PCR positive solid malignancy were screened. Thirty-two patients were included in the study. The median time between the first COVID-19 infection and reinfection was 46 (30-194) days. The reinfection rate was 3.1%. The most common cancer subtype was lung cancer. Mortality rate of reinfection was 34.3% (n=11). Ferritin and creatinine values of serum parameters in reinfection were found to be significantly higher compared to the first infection, respectively (p:0.015, p:0.014). Nine patients with only 1 comorbidity had higher mortality (p=0.052). During reinfection period rate of patients hospitalized in intensive care unit was significantly higher compared with rate of patients during first COVID-19 infection (p:0.002). The mortality rate in 8 patients using antiaggregant or anticoagulant for a long time was not statistically different from the group who did not use it (p:0.681). Conclusions: Solid cancer patients have a higher mortality rate in COVID-19 reinfection. The reinfection rate was 3.1%. This study demonstrated one of the first preliminary clinical results of COVID-19 reinfection in solid cancer patients. Legal entity responsible for the study: Oktay Unsal. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []